Capital in global health broadly takes two forms: philanthropic or commercial.
No matter what side vou are on, capital is allocated based on the potential to maximize returns.
What happens when health markets ignore welfare maximisation in favour of monetary return?
1. Capital flows toward scalable, revenue-generating models
2. Output metrics substitute for welfare metrics
3. Cross-sector capital allocation becomes difficult to compare
As more capital flows into global health, can welfare-adiusted metrics like DALYs complement mainstream decision-making in impact investment?
Curious to know how others think about balancing capital efficiency with welfare efficiency
